News

Pfizer should have different top-selling drugs in 2030 with a heavier focus on oncology. The drugmaker should be more ...
The triple-negative breast cancer market is expected to grow due to rising incidence rates, increasing awareness, advancements in targeted therapies, ongoing clinical trials, improved diagnostics ...